Date: 2015-03-11
Type of information: Licensing agreement
Compound: EB66® cell line for the development of viral veterinary vaccines
Company: Valneva (France- Austria) undisclosed European veterinary company
Therapeutic area: Veterinary medicine
Type agreement: licensing commercialisation
Action mechanism:
Disease:
Details: * On March 11, 2015, Valneva announced that it has signed a commercial license agreement with an undisclosed European company to develop viral veterinary vaccines using Valneva’s EB66® vaccine cell line platform. The commercial license will give Valneva’s new partner the rights to conduct field trials with its selected vaccine candidates using the EB66® platform and to commercialize the vaccines once they have received marketing approval. Valneva is looking forward to reinforcing this new collaboration in the future.
Financial terms: Under the financial terms of the commercial license agreement, Valneva will receive annual maintenance fees and is eligible to receive milestone payments upon the successful achievements of product candidates, along with future royalties on net sales.
Latest news:
